A Q&A With The Experts: Dealing With Complex Drugs In Clinical Development

The market for small molecules is constantly growing and changing – this year, the pipeline for small molecule drug candidates exceeded 8,000, with strong funding behind the range of promising therapeutics in development. The increasing complexity of the drugs currently in clinical development has created mounting pressure for companies hoping to surmount the myriad of challenges that typify these therapeutic modalities. Central to this pursuit is partnering with a contract development and manufacturing organization (CDMO) with the capabilities and flexibility required to achieve the clinical milestones necessary to a drug’s ultimate commercial success.

In a recent webinar, “How to Deal with the Complexity of Drugs in Clinical Development,” Giovanna Libralon, senior director of commercial development at Lonza, and Conrad Roten, group leader for API development services, shared insights into Lonza’s approach to integrated small molecule development.